pdufa.bio

REDEMPLO (plozasiran)

Updated ยทnext FDA decision on the calendar

REDEMPLO (plozasiran) 1 FDA decision on record below. Every date links its source.

ARWR catalyst hub

About this program

We track 1 catalyst event for this program: 0 upcoming and 1 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

PDUFA · Nov 18, 2025 ✓ ApprovedARWR

Questions

When is REDEMPLO (plozasiran)'s next FDA decision or readout?

No upcoming catalyst is on our calendar for REDEMPLO (plozasiran); 1 FDA decision is on record below.

What happened at REDEMPLO (plozasiran)'s most recent FDA decision?

On Nov 18, 2025 the FDA approved the application. The decision page carries the source document and the measured share-price reaction.

Has REDEMPLO (plozasiran) been approved by the FDA?

Yes. The FDA approved an application for REDEMPLO (plozasiran) on Nov 18, 2025; the decision page linked above carries the source.

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings; every date on this page links its source.